Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pennell, P. B.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pennell, P. B.
Right arrow Articles by Macdonald, R. L.
NEUROLOGY 1995;45:456-460
© 1995 American Academy of Neurology

Aplastic Anemia in a Patient Receiving Felbamate for Complex Partial Seizures

Page B. Pennell, MD, Mohammed S. Ogaily, MD and Robert L. Macdonald, MD, PhD

Article abstract-A 53-year-old woman began taking felbamate for uncontrolled complex partial seizures. Four months later, she developed fatigue and ecchymotic skin lesions. Laboratory studies revealed very severe aplastic anemia. There have been an additional nine reported cases of aplastic anemia in the setting of felbamate treatment. The association between felbamate and aplastic anemia has resulted in a joint recommendation by the US Food and Drug Administration and the manufacturer of felbamate, Carter-Wallace, Inc., for the immediate withdrawal of patients from treatment with felbamate.

NEUROLOGY 1995;45: 456-460




This article has been cited by other articles:


Home page
 NeurologyHome page
E. R. Somerville
Aggravation of partial seizures by antiepileptic drugs: Is there evidence from clinical trials?
Neurology, July 9, 2002; 59(1): 79 - 83.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. W. Wheless
Use of Topiramate in Childhood Generalized Seizure Disorders
J Child Neurol, December 1, 2000; 15(1_suppl): S7 - S13.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. M. Dieckhaus, T. A. Miller, R. D. Sofia, and T. L. Macdonald
A Mechanistic Approach to Understanding Species Differences in Felbamate Bioactivation: Relevance to Drug-Induced Idiosyncratic Reactions
Drug Metab. Dispos., July 1, 2000; 28(7): 814 - 822.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
C. D. Thompson, T. A. Miller, M. T. Barthen, C. M. Dieckhaus, R. D. Sofia, and T. L. Macdonald
The Synthesis, In Vitro Reactivity, and Evidence for Formation in Humans of 5-Phenyl-1,3-oxazinane-2,4-dione, a Metabolite of Felbamate
Drug Metab. Dispos., April 1, 2000; 28(4): 434 - 439.
[Abstract] [Full Text]

Home page
 NeurologyHome page
R. C. Sachdeo, T. A. Glauser, F. Ritter, R. Reife, P. Lim, and G. Pledger
A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome
Neurology, June 1, 1999; 52(9): 1882 - 1882.
[Abstract] [Full Text]

Home page
 CLIN PEDIATRHome page
T. F. Barron and S. L. Hunt
A Review of the Newer Antiepileptic Drugs and the Ketogenic Diet
Clinical Pediatrics, September 1, 1997; 36(9): 513 - 521.
[Abstract] [PDF]

Home page
 StrokeHome page
C. G. Wasterlain, L. M. Adams, J. K. Wichmann, R. D. Sofia, and J. MacManus
Felbamate Protects CA1 Neurons From Apoptosis in a Gerbil Model of Global Ischemia
Stroke, July 1, 1996; 27(7): 1236 - 1240.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.